Cara Therapeutics Inc (CARA)
0.7747
+0.04
(+4.90%)
USD |
NASDAQ |
May 02, 16:00
0.7747
0.00 (0.00%)
After-Hours: 17:15
Cara Therapeutics Cash from Operations (Quarterly): -17.37M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -17.37M |
| September 30, 2023 | -19.64M |
| June 30, 2023 | -20.44M |
| March 31, 2023 | -34.62M |
| December 31, 2022 | -23.51M |
| September 30, 2022 | -25.19M |
| June 30, 2022 | -4.503M |
| March 31, 2022 | -25.52M |
| December 31, 2021 | -1.245M |
| September 30, 2021 | -14.12M |
| June 30, 2021 | -21.00M |
| March 31, 2021 | -23.72M |
| December 31, 2020 | 82.09M |
| September 30, 2020 | -21.62M |
| June 30, 2020 | -27.65M |
| March 31, 2020 | -38.30M |
| December 31, 2019 | -31.17M |
| September 30, 2019 | -25.64M |
| June 30, 2019 | -24.90M |
| March 31, 2019 | -27.53M |
| December 31, 2018 | -24.36M |
| September 30, 2018 | -20.49M |
| Date | Value |
|---|---|
| June 30, 2018 | 41.02M |
| March 31, 2018 | -18.47M |
| December 31, 2017 | -11.41M |
| September 30, 2017 | -9.851M |
| June 30, 2017 | -11.93M |
| March 31, 2017 | -21.64M |
| December 31, 2016 | -13.19M |
| September 30, 2016 | -12.90M |
| June 30, 2016 | -11.46M |
| March 31, 2016 | -9.833M |
| December 31, 2015 | -4.168M |
| September 30, 2015 | -7.815M |
| June 30, 2015 | -4.254M |
| March 31, 2015 | -5.241M |
| December 31, 2014 | -5.824M |
| September 30, 2014 | -4.488M |
| June 30, 2014 | -4.239M |
| March 31, 2014 | -3.091M |
| December 31, 2013 | -5.064M |
| September 30, 2013 | -3.441M |
| June 30, 2013 | 13.15M |
| March 31, 2013 | -1.819M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-38.30M
Minimum
Mar 2020
82.09M
Maximum
Dec 2020
-16.74M
Average
-23.51M
Median
Dec 2022
Cash from Operations (Quarterly) Benchmarks
| Nektar Therapeutics | -47.05M |
| Stereotaxis Inc | -2.439M |
| Cerus Corp | -15.18M |
| Avid Bioservices Inc | 3.687M |
| Rigel Pharmaceuticals Inc | -6.24M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -30.20M |
| Cash from Financing (Quarterly) | 36.48M |
| Free Cash Flow | -94.45M |
| Free Cash Flow Per Share (Quarterly) | -0.3565 |
| Free Cash Flow to Equity (Quarterly) | -19.42M |
| Free Cash Flow Yield | -225.2% |